Establishment of cocrystal cocktail grinding method for rational screening of pharmaceutical cocrystals

International Journal of Pharmaceutics

Volumn 437, Issue 1-2, 2012, Pages 162-171

  Yamamoto, Katsuhiko ^a   Tsutsumi, Shunichirou ^a   Ikeda, Yukihiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Amorphous; Cocrystal; Crystallinity; Drug substance; Grinding; Physicochemistry

Indexed keywords

CARBAMAZEPINE; DRUG SOLVENT; PIROXICAM; SPIRONOLACTONE;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL INTERACTION; COCRYSTAL COCKTAIL GRINDING METHOD; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; FEASIBILITY STUDY; GRINDING; MOLECULE; PHARMACEUTICAL COCRYSTAL; PRIORITY JOURNAL; SYNTHESIS; THERMAL ANALYSIS; X RAY POWDER DIFFRACTION;

CARBAMAZEPINE; CRYSTALLIZATION; POWDER DIFFRACTION; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; X-RAY DIFFRACTION;

EID: 84865532216     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.07.038     Document Type: Article

References (28)

1. C.B. Aakeröy, A.M. Beatty, and B.A. Helfrich Total synthesis supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules Angew. Chem. Int. Ed. 40 2001 3240 3242
2. A. Ainouza, J-R. Authelina, P. Billot, and H. Liebermanb Modeling and prediction of cocrystal phase diagrams Int. J. Pharm. 374 2009 82 89
3. Ö. Almarsson, and M.J. Zaworotko Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun. 17 2004 1889 1896
4. S. Basavoju, D. Bostrom, and S.P. Velaga Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization Pharm. Res. 25 2008 530 541
5. R.A. Chiarella, R.J. Davey, and M.L. Peterson Making co-crystals the utility of ternary phase diagrams Cryst. Growth Des. 7 2007 1223 1226
6. N. Chieng, M. Hubert, D. Saville, T. Rades, and J. Aaltonen Cocrystals prepared by mechanical activation formation kinetics and stability of carbamazepine-nicotinamide Cryst. Growth Des. 9 2009 2377 2386
7. S.L. Childs, and K.I. Hardcastle Cocrystals of piroxicam with carboxylic acids Cryst. Growth Des. 7 2007 1291 1304
8. S.L. Childs, N. Rodriguez-Hornedo, L.S. Reddy, A. Jayasankar, C. Maheshwari, L. McCausland, R. Shipplett, and B.C. Ctahly Screening strategy based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine Cryst. Eng. Commun. 10 2008 856 864
9. T. Friščić, and W. Jones Recent advances in understanding the mechanism of cocrystal formation via grinding Cryst. Growth Des. 9 2009 1621 1637
10. T. Fukami, T. Furuishi, T. Suzuki, S. Hidaka, H. Ueda, and K. Tomono Improvement in solubility of poorly water soluble drug by cogrinding with highly branched cyclic dextrin J. Inclusion Phenom. Macrocycl. Chem. 56 2006 61 64
11. M.B. Hickey, M.L. Peterson, L.A. Scoppettuolo, S.L. Morrisette, A. Vetter, J.F. Hector Guzmań Remenar, Z. Zhang, M.D. Tawa, S. Haley, M.J. Zaworotko, and Ö. Almarsson Performance comparison of a co-crystal of carbamazepine with marketed product Eur. J. Pharm. Biopharm. 67 2007 112 119
12. A. Jayasankar, A. Somwangthanaroj, Z.J. Shao, and N. Rodriguez-Hornedo Cocrystal formation during cogrinding and storage is mediated by amorphous phase Pharm. Res. 23 2006 2381 2392
13. S. Karki, T. Friščić, W. Jones, and W.D.S. Motherwell Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding Mol. Pharm. 4 2007 347 354
14. T. Kojima, S. Tsutsumi, K. Yamamoto, Y. Ikeda, and T. Moriwaki High-throughput cocrystal slurry-screening by use of in situ raman microscopy and multi-well plate Int. J. Pharm. 399 2010 52 59
15. H-G. Lee, G.G.Z. Zhang, and D.R. Flanagan Cocrystal intrinsic dissolution behavior using a rotating disk J. Pharm. Sci. 100 2011 1727 1735
16. W. Limwikrant, K. Higashi, K. Yamamoto, and K. Moribe Characterization of ofloxacin-oxalic acid complex by PXRD, NMR and THz spectroscopy Int. J. Pharm. 382 2009 50 55
17. D.P. McNamara, S.L. Childs, J. Giordano, A. Iarriccio, J. Cassidy, M.S. Shet, R. Mannion, E. O'Donnell, and A. Park Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 23 2006 1888 1897
18. J.F. Remenar, S.L. Morissette, M.L. Peterson, B. Moulton, J.M. MacPhee, R. Héctor, H.R. Guzmán, and Ö. Almarsson Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids J. Am. Chem. Soc. 125 2003 8456 8457
19. N. Rodriguez-Hornedo, S.J. Nehm, K.F. Seefeldt, Y. Pagań-Torres, and C.J. Falkiewicz Reaction crystallization of pharmaceutical molecular complexes Mol. Pharm. 3 2005 362 367
20. R.R. Schartman On the thermodynamics of cocrystal formation Int. J. Pharm. 365 2009 77 80
21. N. Schultheiss, and A. Newman Pharmaceutical cocrystals and their physicochemical properties Cryst. Growth Des. 9 2009 2950 2967
22. K. Seefeldt, J. Miller, F. Alvarez-Núňez, and N. Rodriguez-Hornedo Crystallization pathways and kinetics of carbamazepine- nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy and calorimetry studies J. Pharm. Sci. 96 2007 1147 1158
23. N. Shan, and M.J. Zaworotko The role of cocrystals in pharmaceutical science Drug Discov. Today 13 2008 440 446
24. N. Takata, K. Shiraki, R. Takano, Y. Hayashi, and K. Terada Cocrystal screening of stanolone and mestanolone using slurry crytallization Cryst. Growth Des. 8 2008 3032 3037
25. N. Takata, R. Takano, H. Uekusa, Y. Hayashi, and K. Terada A spironolactone-saccharin 1:1 cocrystal hemihydrate Crys. Growth Des. 10 2010 2116 2122
26. A.V. Trask, W.D.S. Motherwell, and W. Jones Physical stability enhancement of theophylline via cocrystallization Int. J. Pharm. 320 2006 114 123
27. S. Tsutsumi, M. Iida, N. Tada, T. Kojima, Y. Ikeda, T. Moriwaki, K. Higashi, K. Moribe, and K. Yamamoto Characterization and evaluation of miconazole salts and cocrystals for improved physicochemical properties Int. J. Pharm. 421 2011 230 236
28. P. Vishweshwar, J.A. McMahon, J.A. Bis, and M.J. Zaworotko Pharmaceutical co-crystals J. Pharm. Sci. 95 2006 499 516